Featured

Searching for Answers; Finding Dignity | Meet a Scientist

Cockroaches after a nuclear war. That is really the best way to understand what Dr. Ugo Cavallaro, a cell biologist and biochemist, is working on in his lab in Milan, Italy…

Read on

Combination Niraparib plus Pembrolizumab Shows Promise

(June 18, 2019) Results of new trials, funded in part by OCRA though the Ovarian Cancer Dream Team and published in JAMA Oncology, show that combination niraparib plus pembrolizumab therapy showed promising antitumor activity in patients with…

Read on

OCRA Funded Research Identifies Genes Associated with Increased Risk of Ovarian Cancer

(May 21, 2019) Earlier this month, Nature Genetics published a study, in part funded by OCRA, that found 34 genes were connected to women developing the earliest stages of ovarian cancer…

Read on

OCRA Wins C2 President’s Award

(May 14, 2019) OCRA  received the President’s Award at the first Cancer Community (C2) Awards, created to recognize individuals and organizations who have created positive change in cancer care…

Read on

National Comprehensive Cancer Network Updates Guidelines

(March 26, 2019) The NCCN, or the National Comprehensive Cancer Network, recently updated its clinical guidelines for the treatment of ovarian cancers…

Read on

OCRA Funded Study Aims to Increase Efficacy of PARP Inhibitors

(March 20, 2019) The Ovarian Cancer Dream Team, funded in part by OCRA, recently completed a Phase 1b Trial, which combined a PARP inhibitor with an HRR (homologous recombination repair) pathway inhibitor, such as PI3K, in order to increase the…

Read on

Lymphadenectomy in Ovarian Cancer Patients Can Be Unnecessary

(March 18, 2019) Before the most recent study on the usage of lymphadenectomy, published earlier this month in the New England Journal of Medicine, it was thought that surgically removing clinically negative lymph nodes had a positive effect on the…

Read on

OCRA-Funded Research Indicates that Stem-Like Cells May Be Key to Preventing Recurrence

(March 15, 2019) Cell Reports recently published a study about a drug that, given in combination with chemotherapy, could greatly increase survival rates of ovarian cancer patients…

Read on

New Therapeutic Approaches for Mucinous Ovarian Cancer

(February 13, 2019) Data from a study conducted by researchers at MD Anderson and Johns Hopkins suggest that an adjuvant gastrointestinal (GI)-based chemotherapy regimen is more beneficial than one that is gynecologic-based in patients with mucinous…

Read on

Drugs to Treat Hypertension May Enhance Ovarian Cancer Drugs

(January 23, 2019) Researchers at Massachusetts General Hospital recently found a correlation between a class of drug used to treat hypertension and longer survival rates in ovarian cancer patients when used with paclitaxel, a drug used to treat…

Read on

OCRA Funded Research Delves Deeper into How PARPi Work

(December 21, 2018) This month, researchers in Boston published their findings on how PARP inhibitors (PARPi) cause a chain reaction of responses from the tumor and its environment…

Read on

FDA Approves Olaparib for Frontline Maintenance Treatment in Ovarian Cancer

(December 20, 2018) Earlier this year a phase III clinical trial, known as SOLO-1, showed that frontline olaparib (Lynparza) can reduce the risk of disease progression or death by up to 70% in women with BRCA 1 or 2 positive, advanced stage…

Read on